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Abstract 
Background:Pediatric neurological disorders can be mainly categorized into four areas such as movement 
disorders, epilepsy associated disorders, neuro-peripheral disorders and neuropsychiatric disorders. They can be 
identified from in-utero to 18 years. The interpretation of sequencing results based on phenotype-genotype 
correlation are important for the clinicians, patients and the family for further treatment and  management.Materials 
& Methods: Sixteen patients were referred to the department of Genetics of a tertiary care hospital for post-test 
counselling along with clinical exome reports. In cases where there was no reported variants, reanalysis of raw data 
was performed using a freeware by Illumina. Variants identified were assessed for genotype-phenotype correlations 
and evaluated by segregation analysis wherever required to arrive at a molecular diagnosis.Results:Six patients had 
a report with a pathogenic sequence variant correlating with the phenotype,   four patients were reported with a 
Variant of Unknown Significance, while the sequence data of remaining six patients was reanalyzed to establish 
diagnosis.Conclusion:Results indicate the important role that a genetic counselor plays in establishing the genotype-
phenotype correlation and providing appropriate post-test genetic counselling to help pediatric neurologists to 
manage patients and assist patients to take informed reproductive/predictive/pre-natal decisions. 
Keywords: neurological,patients,genetics,hospital 
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Introduction  
 
Pediatric neurology is one of the most complex areas of 
medical practice as diagnosing neonates and children 
with neurological symptoms is of prime importance 
both for appropriate management by early intervention, 
predicting prognosis and genetic counseling for  
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recurrence risk to plan subsequent pregnancies.  
Neurological disorders can be caused due to infection, 
perinatal trauma or underlying genetic pathology [1]. It 
is important for clinicians to differentiate the cause to 
manage patients appropriately. Pediatric neurological 
disorders are a complex heterogenous group of diseases 
with overlapping symptoms and a subset of these have 
a well-defined genetic cause [2]. It is important to 
understand, recognize and record the progressive 
clinical manifestations observed in patients, as this 
helps in diagnosis using the most suitable genetic tests. 
Although neuroimaging, biochemical analyses of body 
fluids and other electrophysiological studies are helpful 
in diagnosis, accurate diagnosis can only be achieved 
after identifying a molecular cause for these complex 
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disorders. Next generation sequencing (NGS) is a 
diagnostic modality which has recently gained a 
prominence in current day medical practice and has the 
capacity to sequence multiple genes, complete exomes 
or genomes, simultaneously. Hence it is a powerful 
tool for investigating pediatric neurological disorders 
[3].NGS plays an important role especially in pediatric 
practice for identifying DNA sequence variants and 
then prioritizing variants correlating with disease 
phenotype of the affected individual [4]. Role of 
Genetic counselors is indispensable in correlating 
phenotype-genotype along with using the pedigree 
information, as well as, databases available to diagnose 
the neurological disorder under investigation. Genetic 
counselors can also help clinicians by facilitating 
testing, understanding the genetic test reports and 
providing the appropriate genetic counselling to the 
patients/families adding value to patient care. In the 
present study, cases from paediatric neurology clinics 
referred to a single Genetic unit will be discussed. All 
the cases had a NGS based panel test report, which was 
carried out on the advice of a pediatric neurologist for 
disease diagnosis. The sequence variants reported or 
identified after reanalysis were correlated with the 
phenotype and diagnosis was established for patient 
management and reproductive counselling. 
 
Method 
Patients who had undergone a NGS test were referred 
by pediatric neurologists for genetic counselling [5]. 
The NGS test results were correlated with the 
phenotype and re-analysis was carried out in cases 
where a diagnosis was not achieved. This was done by 
procuring the raw sequence data in the form of variant 
caller file (.vcf). Using an in-silico software, Illumina 
Basespace, a cloud-based software tool used as a 
platform to interpret, report and analyse variants from 
the genomic data.  Variants which were pathogenic, 
likely pathogenic or VUS were correlated with the 
phenotypic features of the proband, the organ systems 
affected, associated specific disease conditions and 
differential diagnosis for the same. Candidate genes 
and the significance of the relevant variants was 
established by searching the literature and databases 
such as ClinVar [6],OMIM [7], Face2Gene [8], 
Genetic home reference [9]. They were then assessed 
by in-silico methods like Mendelian Clinically 
Applicable Pathogenicity Score(M-CAP) [10], The 
scale-invariant feature transform (SIFT), 
Polymorphism Phenotyping v2(Polyphen) to  confirm 
functional significance. Once the genotype -phenotype 
correlation was documented, the family was counselled 
forsanger confirmation and segregation analysis to 
further confirm the relevance of the identified variants 
in the patients.Informed Consent was taken from 
patients/parents/guardians prior to obtaining 2ml of 
peripheral blood in EDTA vacutainers as per the 
Institutional Ethics Committee of Kamineni Hospitals 
(Registration #ECR/58/Inst/AP/2013) guidelines. This 
study was carried out in accordance with the 
recommendations of the International Council of 
Harmonisation and Good Clinical Practice. All 
subjects/families gave written informed consent in 
accordance with Declaration of Helsinki. 
 
Results 
 
Sixteen patients which included seven females and nine 
males between the ages of 3 days and 16 years were 
referred for test based counseling with an NGS report 
from a commercial company. Patients were assessed 
for genotype–phenotype correlation with the sequence 
variants reported. Ten out of sixteen (62.5%) patients 
had a diagnosis from results given by the company 
(Table 1). Six of these patients (37.5%) were identified 
with a pathogenic variant, while four patients (25%) 
were identified with variants of unknown significance 
(VUS). Further confirmation of the variants was done 
by segregation analysis in the parents. Re-analysis of 
the raw  sequence data was done for the remaining six 
patients, where the company did not report any 
clinically significant variants. Diagnosis could be 
established for all of them (Table 1). The different 
neurological disorders that were diagnosed were 
categorized into neuro-peripheral disorders (Case a.1-
a.6), movement disorders (Case b.1-b.3), epilepsy 
associated disorders (Case c.1-c.5) and 
neuropsychiatric disorders (Case d.1-d.2) based on the 
review by Hung et al (2014). 
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Case no. Age/Sex Clinical details Genotype 
Disorder/Pattern of 
inheritance 
Case a.1 1y/F 
Global development 
delay, Krabbe disease, 
seizures, muscle 
weakness, vision 
disorder and hearing 
defect 
PIEZO2- 
c.C1156T/p.R386
W 
Heterozygous 
Known and 
pathogenic 
variant 
Marden-Walker 
syndrome/Autosomal 
dominant 
(OMIM #248700) 
Case a.2 
3y11m/ M 
Global development 
delay, seizures, muscle 
eye brain disease and 
suspicion of Fukuyama 
congenital muscular 
dystrophy 
ADGRG1 
c.C1693T/p.Arg5
65T 
Homozygous 
Known and 
pathogenic 
variant 
Bilateral frontoparietal 
polymicrogyria 
(BFPP)/Autosomal 
recessive 
(OMIM #606854) 
Case a.3 
1y/F 
Intellectual disability, 
global development 
delay, Hypertonia 
AUTS2 
c.G2521A/p.D84
1N 
Heterozygous 
Known and 
pathogenic 
variant 
Mental Retardation, 
AD26/Autosomal 
Dominant 
(OMIM #607270) 
Case a.4 1y/M 
Development delay, 
strabismus, slight 
nystagmus, cerebellar 
atrophy 
EXOSC3 
c.395A>C 
p.Asp132Ala  
Homozygous 
Pathogenic 
  Pontocerebellar 
hypoplasia, type 1B 
/Autosomal recessive 
Case a.5 1y/M 
Developmental 
delays/Refractory 
convulsions 
MMACHC 
c.C394T/p.Arg13
2X Homozygous 
Known and 
pathogenic 
Methylmalonic aciduria 
and homocystenuria, 
cb1C type Autosomal 
recessive 
(OMIM #609831) 
Case a.6 
 
 
16y/M 
Global development 
delay with delayed 
milestones, No neck 
holding and no eye 
contact. 
Episodes of seizures 
NFU1 
c.334G>A/p.Val1
12Ile 
Homozygous 
Likely Pathogenic 
Multiple Mitochondrial 
dysfunctions syndrome 
1 Autosomal Recessive 
(OMIM #605711) 
Case a.7 
1y8m/F 
Global development 
delay with delayed 
milestones Neuro-
regression from 6 
months of age, 
no eye contact, no 
social smile 
AGRN 
c.5645C>T 
p.(Thr1882Ile) 
Homozygous 
VUS 
Myasthenic syndrome, 
congenital, 8, with pre- 
and postsynaptic 
defects 
Autosomal Recessive 
 
(OMIM #103320) 
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Case b.1 
13y/F 
Neuroregression, 
Lower limb weakness 
NIPA1 
c.45_47dupGGC 
p.(Ala16dup) 
Heterozygous 
VUS 
Spastic paraplegia 6 
Autosomal Dominant 
 
(OMIM #600363) 
Case b.2 8y/M 
Neurodegenerative 
disorder with suspicion 
of Alexander/vanishing 
white matter disease 
ASPA 
c.237-1G>T 
Homozygous VUS 
Canavan disease 
Autosomal recessive 
 
(OMIM #271900)` 
Case c.1 
1y/M 
 
 Seizures and 
Development Regression 
STXBP1 
c.673A>T 
p.Lys22 
Heterozygous 
Pathogenic 
Epileptic 
Encephalopathy, early 
infantile 4, 
Autosomal Dominant 
 
(OMIM #612164) 
Case c. 2 4m/F 
Developmental delay, 
progressive dystonia, 
occular abnormalities 
TPP1 
c.887-6delA 
Homozygous 
VUS 
      Ceroid lipofuscinosis, 
neuronal, 2 
Autosomal Recessive 
 
      (OMIM #204500) 
Case c.3 3d/F 
 
Antenatal scan showed 
IUGR with 
microcephaly, 
neonatal death on 
third day 
POMT1 
c.123-4C>T & 
POMT1 
c.280+7_280+8d
elGA 
Compound 
Heterozygous 
VUS 
Walker-Walberg Syndrome 
Autosomal Recessive 
Case c.4 2m/M Tuberous Sclerosis 
TSC2 
c.T4724C/p. 
Leu1575pro 
Heterozygous 
VUS 
Tuberous Sclerosis – 2
 
Autosomal dominant 
 
(OMIM #613254) 
Case c.5 
 
6y4m/ M 
Choreoathetosis and 
suspicion of 
Neurotransmitter 
disease, global 
development delay 
MDH2 
c.G916A/p.G306
S 
Homozygous 
VUS 
Epileptic 
Encephalopathy early 
infantile, 51 
Autosomal Recessive 
 
(OMIM #617339) 
Case d.1 8y/F 
Hyperactivity, 
Neurotransmitter 
deficiency, 
Development delay, 
Neuro regression 
GLI2 
c.T4560G/p.D152
0E 
Heterozygo
us Known and 
Pathogenic 
Culler-Jones Syndrome 
Autosomal Dominant 
 
(OMIM #615849) 
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Table 1: showing the genotype and phenotype data of 16 neuropediatric case 
 
 
a) Neuro-peripheral disorder 
Five cases from this category had a molecular 
diagnosis based on specific pathogenic variants, while  
 
one had a VUS. Pathogenic heterozygous variant 
c.C1156T in the PIEZO2 gene causative of Marden-
Walker syndrome (OMIM #248700) and c.G2521 in 
the AUTS2 gene causative of Mental Retardation, 
AD26,(OMIM #607270), which are autosomal 
dominant disorders were identified in Case a.1 and 
Case a. 3 respectively, which correlated with 
phenotype of the probands (Table 1). Case a.2 and 
Case a.4 had homozygous pathogenic variants 
c.C1693T/p.Arg565T in ADGRG1gene causative of 
Bilateral frontoparietalpolymicrogyria, (OMIM 
#606854) and c.395A>C in the EXOSC3 gene 
consistent with Pontocerebellar Hypoplasia 1B, 
respectively. Case a.5 was referred in view of 
refractory convulsions and development delays and 
was diagnosed with a homozygous, pathogenic variant 
c. C394T/p.Arg132X in MMACHC gene causative of 
Methylmalonic aciduria and homocystenuria, cb1C 
type Autosomal recessive(OMIM #609831). Case a.6 
was identified with homozygous VUS in NFU1 gene 
associated with Multiple Mitochondrial dysfunctions 
syndrome 1 (OMIM #605711) which is an autosomal 
recessive condition. Case a.7 was identified with 
homozygous VUS in the AGRN gene causative of 
Myasthenic syndrome, congenital, 8, with pre- and 
postsynaptic defects (OMIM #103320). 
b) Movement disorders 
The two movement disorders were identified with 
VUS: Case b.1 was identified with a heterozygous 
VUS c.45_47dupGGC in NIPA1 gene causative of 
Spastic paraplegia 6 (OMIM #600363) which is an 
autosomal dominant disorder. While Case b.2 was 
identified with homozygous VUS in the ASPA gene 
c.237-1G>T causative of Canavan disease (OMIM 
#271900), an autosomal recessive disorders. 
c) Epilepsy associated disorders 
All cases except one with seizure disorders had VUS in 
genes associated with various neurological disorders. 
Case c.1 was identified to have a novel heterozygous 
stop gain variant in STXBP1 gene responsible for 
Epileptic encephalopathy, early infantile, 4 (OMIM: 
612164). Segregational analysis revealed that the 
variant was denovo in the proband. Case c.2 is a female 
child aged 4 months with non-consanguineous parents, 
and an intronic homozygous variant altering splice 
region was detected in  TPP1 gene causative of Ceroid 
lipofuscinosis, neuronal, 2 (OMIM 204500). 
Segregation analysis, showed that the parents were 
heterozygous for the variant supporting its functional 
significance. Case c.4 was clinically diagnosed with 
Tuberous Sclerosis in view of multiple hypopigmented 
patches and  sequencing reported a VUS in TSC2 gene 
correlating with Tuberous sclerosis 2 (OMIM 
#613254). Case c.5 had a homozygous VUS in MDH2 
gene consistent with a diagnosis of Epileptic 
Encephalopathy early infantile, 51. It is an autosomal 
recessive disorder. (OMIM #617339). Case c.3 is a 
neonatal autopsy sample  from a 3 day old infant of a 
3rd degree consanguineous couple (female - 23 years 
and her husband 30yrs) who also had a history of 
another neonatal death with features of Walker-
Walberg Syndrome. Data analysis revealed two 
variants in POMT1 gene c.123-4C>T and POMT1 
c.280+7_280+8delGA. Segregational analysis 
indicated that both the parents were heterozygous 
(carriers) for the c.280+7_280+8delGA variant, 
indicating that the c.123-4C>T variant is most likely a 
germline mosaicisim in one of the parents. 
 
d) Neuropsychiatric disorders 
There were two cases under this category Case d.1 with 
hyperactivity, Neurotransmitter deficiency, 
Development delay, Neuro regression who was 
Case d.2 7y/M 
Developmental Delay, 
ADHD, Autism, 
Nephrotic Syndrome, 
Myopia Microarray 
showed LOH in Chr19 
q13.2 associated with 
renal issues. 
SYN1 
c.1554delC 
p.(Ala519ArgfsTe
r148) 
CACNA1H 
c.1495G>A 
p.(Gly499Ser) 
VUS 
 
Autism Spectrum 
Disorder 
(OMIM #300491) 
Nephrotic Syndrome 
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identified with a pathogenic variant c.T4560G in the 
GLI2 gene associated with the Culler-Jones Syndrome 
(OMIM 615849). While Case d.2 was referred in view 
of autism with nephrotic syndrome. CES revealed two 
heterozygous VUS: (i) c.1554delC 
p.(Ala519ArgfsTer148) in SYN1 gene and (ii) 
c.1495G>A p.(Gly499Ser) in CACNA1H gene 
associated with ASD (OMIM 300491 and 607904 
respectively).  
 
Discussion 
Pediatric neurological disorders  have overlapping but 
distinct features, hence molecular analysis is important 
to diagnose the disorders for proper management and 
appropriate genetic counseling, for prevention in the 
future generations. They are generally categorized into 
four clinical types such as movement disorders, neuro-
peripheral disorders, epilepsy associated disorders, and 
neuropsychiatric disorders . The study was carried out 
in sixteen patients who were tested by NGS - 
Neurological gene panel available in commercial 
companies and by reanalysis assessing all gene variants 
reported.Seven were diagnosed as neuroperipheral 
disorders, five of these cases had a pathogenic variant 
(Case a.1 - a.5), one had a likely pathogenic variant 
(Case a.6) indicating that the neurological panel of 
genes evaluated in companies are mostly associated 
with this category of disorders. Re-analysis followed 
by genotype-phenotype correlation identified a de-novo 
pathogenic variant in the STXBP1 gene helping in the 
diagnosis of Case c.1 as Epileptic Encephalopathy, 
early infantile 4. This was confirmed by Segregation 
analysis of parents and helped in future reproductive 
counseling. Another pathogenic variant 
T4560G/p.D1520E was reported in the GLI1 gene 
associated with Culler-Jones Syndrome (Case d.1) 
under Neuro-psychiatric disorders.  
Commercial testing also reported four VUSs, one 
diagnosed as a neuroperipheral disorder (Case a.7), one 
as a movement disorder (Case b.2) and two as epilepsy 
disorders (Cases c.4, c.5). All these require further 
functional analysis and maybe novel variants unique to 
our population. Reanalysis found  VUS in genes 
associated with movement disorders (Cases b.1 and 
b.2), epilepsy disorders (Cases c.2 and c.3) and 
neuropsychiatric disorders (Case d.2). Case d.2 was 
diagnosed with two causative gene variants c.1554delC 
/ p.(Ala519ArgfsTer148) in the SYN1 gene and 
c.1495G>A / p.(Gly499Ser) variants in the CACNA1H 
gene associated with Autism Spectrum Disorder 
(OMIM 300491). Segregation analysis in the parents 
confirmed that SYN1 gene was causative of the 
disorder. 
This study demonstrates that NGS panel testing can 
help in exact molecular diagnosis of patients with 
similar clinical phenotypes in a clinical setting. The 
current neurological panel of genes available with 
companies needs to be expanded to cover genes 
responsible for other categories of pediatric 
neurological disorders apart from the neuro-peripheral 
disorders. Since the NGS provides a powerful platform 
to sequence multiple genes simultaneously, it is 
important to design and develop the right panel of 
multiple genes that cover and target the total spectrum 
of pediatric neurological disorders.Our study also 
highlights the importance of genetic counseling 
sessions during the diagnostic process. Since the setup 
is pediatric, it is presumable that the patients and their 
immediate families are in their reproductive ages. Five 
cases in addition to syndromic counseling about the 
diagnosis also received comprehensive reproductive 
counseling to guide and empower them to take 
informed decisions. Three of which planned their 
subsequent pregnancies after the counseling and also 
underwent prenatal testing. In other two cases, 
adequate pre-natal counseling was offered for future 
pregnancies. It is important for clinicians to analyze not 
only the clinical features but also the complex genetic 
aspect of these neurological conditions to be able to 
offer the most appropriate management/treatment to 
the patients. Incorporating pre and post genetic 
counseling sessions before advising a genetic test can 
be helpful for both the clinicians and the patients. This 
will help in making the diagnosis much easier and help 
to establish the correct genotype-phenotype correlation. 
The value added by genetic counselor can be further 
enhanced if advanced in-silico and functional studies 
along with the right genetic tests are carried out to 
validate the variants to establish the appropriate 
diagnosis. This emphasizes the need for genetic 
counselors to be part of a core team involved with both 
the diagnosing physician and the molecular testing 
laboratories to achieve accurate diagnosis.  
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